October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...
Interstitial Lung Disease (ILD): In the PHAROS trial, 1 patient (1%) receiving MEKTOVI with BRAFTOVI developed pneumonitis. Assess new or progressive unexplained pulmonary symptoms or findings for ...
of patients treated with ensartinib reached 24-month disease-free survival, compared to 53.5% in the placebo control arm.
The agency’s decision to conceal drug names on inspection reports has prevented doctors, pharmacists and patients from ...
Read here for an analysis of Thermo Fisher (TMO) stock's Q3 2024 growth, major stock buyback, and how Fed rate cuts boost ...
Zacks Investment Research on MSN
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space. Oncology or ...
GSK tried again with the combination regimens, and two separate Phase 3 trials yielded promising results in 2024. In the ...
The consumer health giant invites suppliers to align with its net zero goals by offering practical tools, targets and ...
He stipulated that the honoree should be a force for good, and selected Pfizer Chairman Albert Bourla for his innovation, ...
A new report from the Institute for Clinical and Economic Review (ICER) in the US has found that the net prices of newly ...
Johnny Cheng, currently CFO of HUTCHMED, has been named acting CEO following the departure of Dr Weiguo Su due to health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback